Inventor
SAMPEI ZENJIRO
SG13 patents
⚠️ This page may combine multiple inventors who share the name “SAMPEI ZENJIRO”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
CHUGAI PHARMACEUTICAL CO LTD
12 patentsUS9765135B2Sep 19, 2017
Anti-C5 antibodies
CHUGAI PHARMACEUTICAL CO LTD51 citations97
US10385122B2Aug 20, 2019
Nucleic acids encoding anti-C5 antibodies
CHUGAI PHARMACEUTICAL CO LTD14 citations93
US10450381B2Oct 22, 2019
Methods of treatment that include the administration of bispecific antibodies
CHUGAI PHARMACEUTICAL CO LTD28 citations92
US10023630B2Jul 17, 2018
Methods of neutralizing C5 with anti-C5 antibodies
CHUGAI PHARMACEUTICAL CO LTD14 citations92
US11597760B2Mar 7, 2023
Method of detecting the presence of complement C5
CHUGAI PHARMACEUTICAL CO LTD6 citations85
US10604561B2Mar 31, 2020
Anti-dengue virus antibodies, polypeptides containing variant Fc regions, and methods of use
CHUGAI PHARMACEUTICAL CO LTD11 citations82
US12187786B2Jan 7, 2025
Anti-dengue virus antibodies, polypeptides containing variant Fc regions, and methods of use
CHUGAI PHARMACEUTICAL CO LTD1 citations71
US10844113B2Nov 24, 2020
Anti-dengue virus antibodies, polypeptides containing variant Fc regions, and methods of use
CHUGAI PHARMACEUTICAL CO LTD2 citations70
US12209121B2Jan 28, 2025
Anti-sclerostin antibodies and methods of use
CHUGAI PHARMACEUTICAL CO LTD0 citations62
US11608374B2Mar 21, 2023
Anti-sclerostin antibodies and methods of use
CHUGAI PHARMACEUTICAL CO LTD1 citations62
US11780908B2Oct 10, 2023
Anti-dengue virus antibodies, polypeptides containing variant FC regions, and methods of use
CHUGAI PHARMACEUTICAL CO LTD0 citations59
US11891432B2Feb 6, 2024
Anti-dengue virus antibodies having cross-reactivity to Zika virus and methods of use
CHUGAI PHARMACEUTICAL CO LTD0 citations56